REGENXBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.19 USD | +0.81% |
|
+3.19% | -9.81% |
| Sales 2024 * | 134M 11.2B | Sales 2025 * | 218M 18.21B | Capitalization | 794M 66.2B |
|---|---|---|---|---|---|
| Net income 2024 * | -211M -17.59B | Net income 2025 * | -134M -11.17B | EV / Sales 2024 * | 4.79 x |
| Net cash position 2024 * | 151M 12.59B | Net cash position 2025 * | 175M 14.55B | EV / Sales 2025 * | 2.84 x |
| P/E ratio 2024 * |
-3.93
x | P/E ratio 2025 * |
-6.81
x | Employees | 344 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on REGENXBIO Inc.
More recommendations
More press releases
| 1 day | +0.81% | ||
| 1 week | +3.19% | ||
| Current month | -23.16% | ||
| 1 month | -23.16% | ||
| 3 months | +27.28% | ||
| 6 months | +12.59% | ||
| Current year | -9.81% |
1 week
15.29
16.66
1 month
15.1821.57
Current year
11.8328.80
1 year
11.8328.80
3 years
11.8346.46
5 years
11.8355.23
10 years
7.0785.10
| Managers | Title | Age | Since |
|---|---|---|---|
Kenneth Mills
FOU | Founder | 49 | 16/08/16 |
Vit Vasista
DFI | Director of Finance/CFO | 56 | 01/09/01 |
| Chief Tech/Sci/R&D Officer | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 03/21/03 |
David Stump
BRD | Director/Board Member | 74 | 15/15/15 |
| Director/Board Member | 71 | 01/15/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.76% | 16 M€ | -8.49% | ||
| 0.25% | 27 M€ | -5.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 16.19 | +0.81% | 305,658 |
| 25/24/25 | 16.06 | +0.12% | 604,238 |
| 24/24/24 | 16.04 | +0.88% | 425,390 |
| 23/24/23 | 15.9 | +1.66% | 360,158 |
| 22/24/22 | 15.64 | -0.32% | 437,246 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.19
USD
Average target price
39.83
USD
Spread / Average Target
+146.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.81% | 794M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RGNX Stock
